Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Cirrhosis

Free Subscription Articles published in Gut Retrieve available abstracts of 37 articles: HTML format

Single Articles

September 2025
1. FENG G, Wong VW, Targher G, Byrne CD, et al
   Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring.
   Gut. 2025;74:1741-1750.
   PubMed     Abstract available
   
   
   August 2025
2. 
   Correction: Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis.
   Gut. 2025;74:e18.
   PubMed    
   
   
   June 2025
3. NIU J, Gao Y, Wang G, Qin Z, et al
   Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial.
   Gut. 2025 Jun 24:gutjnl-2025-335577. doi: 10.1136/gutjnl-2025-335577.
   PubMed     Abstract available
   
   
   
4. CHEN J, Xu X, Yang S, Yu X, et al
   Validation of the CLIF-SIG score in patients with HBV-related acutely decompensated cirrhosis.
   Gut. 2025 Jun 19:gutjnl-2025-335810. doi: 10.1136/gutjnl-2025-335810.
   PubMed    
   
   
   April 2025
5. PINTER M, Fulgenzi CAM, Pinato DJ, Scheiner B, et al
   Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction.
   Gut. 2025 Apr 29:gutjnl-2025-334928. doi: 10.1136/gutjnl-2025-334928.
   PubMed     Abstract available
   
   
   February 2025
6. TREBICKA J, Aguilar F, Queiroz Farias A, Lozano JJ, et al
   Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis.
   Gut. 2025 Feb 26:gutjnl-2024-333876. doi: 10.1136/gutjnl-2024-333876.
   PubMed     Abstract available
   
   
   November 2024
7. MAO X, Zhang X, Kam L, Chien N, et al
   Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
   Gut. 2024;73:2054-2061.
   PubMed     Abstract available
   
   
   
8. SINGAL AG, Narasimman M, Daher D, Yekkaluri S, et al
   Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial.
   Gut. 2024;73:2037-2044.
   PubMed     Abstract available
   
   
   October 2024
9. VAN DER MERWE SW, G Fernandez-Barrena M
   Safe and successful gut-restricted adsorbent strategy against cirrhosis and acute-on-chronic liver failure.
   Gut. 2024 Oct 26:gutjnl-2024-332457. doi: 10.1136/gutjnl-2024-332457.
   PubMed    
   
   
   
10. LINK F, Li Y, Zhao J, Munker S, et al
    ECM1 attenuates hepatic fibrosis by interfering with mediators of latent TGF-beta1 activation.
    Gut. 2024 Oct 24:gutjnl-2024-333213. doi: 10.1136/gutjnl-2024-333213.
    PubMed     Abstract available
    
    
    
11. 
    Correction: Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation.
    Gut. 2024;73:e32.
    PubMed    
    
    
    
12. SHANG Y, Akbari C, Dodd M, Nasr P, et al
    Cause of death by fibrosis stage in 959 patients with biopsy-proven NAFLD.
    Gut. 2024;73:e30.
    PubMed    
    
    
    September 2024
13. ZIPPRICH A, Hernaez R
    High-risk varices in patients with Child-Pugh-Turcotte B and C: consider band ligation with carvedilol for preventing first variceal bleeding, especially in patients with MASLD-associated cirrhosis.
    Gut. 2024 Sep 18:gutjnl-2024-333263. doi: 10.1136/gutjnl-2024-333263.
    PubMed    
    
    
    August 2024
14. YANG AH, Tincopa MA, Tavaglione F, Ajmera VH, et al
    Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA.
    Gut. 2024 Aug 7:gutjnl-2024-332917. doi: 10.1136/gutjnl-2024-332917.
    PubMed     Abstract available
    
    
    July 2024
15. TEVETHIA HV, Pande A, Vijayaraghavan R, Kumar G, et al
    Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.
    Gut. 2024 Jul 27:gutjnl-2023-331181. doi: 10.1136/gutjnl-2023-331181.
    PubMed     Abstract available
    
    
    May 2024
16. BABUTA M, Morel C, de Carvalho Ribeiro M, Calenda C, et al
    Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcohol-induced acceleration of MASH fibrosis.
    Gut. 2024 May 22:gutjnl-2023-331447. doi: 10.1136/gutjnl-2023-331447.
    PubMed     Abstract available
    
    
    April 2024
17. BREITKOPF-HEINLEIN K, Martinez-Chantar ML
    Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?
    Gut. 2024 Apr 25:gutjnl-2023-331785. doi: 10.1136/gutjnl-2023-331785.
    PubMed    
    
    
    
18. LIU J, MacNaughtan J, Kerbert AJC, Portlock T, et al
    Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis.
    Gut. 2024 Apr 15:gutjnl-2023-330699. doi: 10.1136/gutjnl-2023-330699.
    PubMed     Abstract available
    
    
    
19. ARMANDI A, Sanavia T, Younes R, Caviglia GP, et al
    Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease.
    Gut. 2024;73:825-834.
    PubMed     Abstract available
    
    
    March 2024
20. TREBICKA J, Hernaez R, Shawcross DL, Gerbes AL, et al
    Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers.
    Gut. 2024 Mar 25:gutjnl-2023-330584. doi: 10.1136/gutjnl-2023-330584.
    PubMed     Abstract available
    
    
    February 2024
21. EL-SERAG H, Kanwal F, Ning J, Powell H, et al
    Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.
    Gut. 2024 Feb 16:gutjnl-2024-332034. doi: 10.1136/gutjnl-2024-332034.
    PubMed     Abstract available
    
    
    January 2024
22. 
    Correction: P23 Opportunistic cirrhosis case finding in alcohol dependent inpatients through alcohol specialist nurse assessment and transient elastography: early detection in a high-risk group.
    Gut. 2024;73:e3.
    PubMed    
    
    
    
23. KONG M, Zhou J, Kang A, Kuai Y, et al
    Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis.
    Gut. 2024 Jan 4:gutjnl-2023-329671. doi: 10.1136/gutjnl-2023-329671.
    PubMed     Abstract available
    
    
    December 2023
24. CHOUIK Y, Levrero M
    Monocyte phenotypic liquid biopsy for NASH and liver fibrosis diagnosis: a new kid on the block.
    Gut. 2023;73:10-11.
    PubMed    
    
    
    November 2023
25. ZHANG X, Yip TC, Wong GL, Leow WX, et al
    Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.
    Gut. 2023;72:2364-2371.
    PubMed     Abstract available
    
    
    
26. 
    Correction: Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
    Gut. 2023;72:e4.
    PubMed    
    
    
    October 2023
27. JUANOLA A, Ma AT, de Wit K, Gananandan K, et al
    Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.
    Gut. 2023 Oct 26:gutjnl-2023-329923. doi: 10.1136/gutjnl-2023-329923.
    PubMed     Abstract available
    
    
    
28. CHOI WM, Kim GA, Choi J, Choi GH, et al
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Gut. 2023 Oct 9:gutjnl-2023-330225. doi: 10.1136/gutjnl-2023-330225.
    PubMed     Abstract available
    
    
    
29. CIOCAN D, Turpin W
    New insights into an old paradigm: why IgA accumulates in alcoholic liver disease and what could be its role.
    Gut. 2023;72:1812-1814.
    PubMed    
    
    
    September 2023
30. MANTOVANI A, Tilg H, Targher G
    FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials.
    Gut. 2023 Sep 27:gutjnl-2023-331115. doi: 10.1136/gutjnl-2023-331115.
    PubMed    
    
    
    July 2023
31. ZHAO L, Wu Q, Li Q, Chen A, et al
    TIPSS plus extrahepatic collateral embolisation may decrease variceal rebleeding and post-TIPSS hepatic encephalopathy.
    Gut. 2023 Jul 31:gutjnl-2023-330255. doi: 10.1136/gutjnl-2023-330255.
    PubMed    
    
    
    
32. HE X, Gao N, Lv F, Wu F, et al
    Temporal trend of mortality in patients with cirrhosis with primary biliary cholangitis and primary sclerosing cholangitis during the COVID-19 pandemic.
    Gut. 2023 Jul 24:gutjnl-2023-330271. doi: 10.1136/gutjnl-2023-330271.
    PubMed    
    
    
    
33. MANTOVANI A, Csermely A, Tilg H, Byrne CD, et al
    Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals.
    Gut. 2023;72:1433-1436.
    PubMed    
    
    
    June 2023
34. WITTKOP L, Boettler T
    More than shots in the dark: driving vaccine efficacy in cirrhosis.
    Gut. 2023 Jun 7:gutjnl-2023-329867. doi: 10.1136/gutjnl-2023-329867.
    PubMed    
    
    
    March 2023
35. GIRALDEZ-GALLEGO A, Rodriguez-Seguel EDP, Valencia-Martin R, Morillo-Garcia A, et al
    Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial.
    Gut. 2023 Mar 24:gutjnl-2022-328222. doi: 10.1136/gutjnl-2022-328222.
    PubMed     Abstract available
    
    
    January 2023
36. RAVAIOLI F, Dajti E, Mantovani A, Newsome PN, et al
    Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis.
    Gut. 2023 Jan 4:gutjnl-2022-328689. doi: 10.1136/gutjnl-2022-328689.
    PubMed     Abstract available
    
    
    June 2022
37. AWONIYI M, Wang J, Ngo B, Meadows V, et al
    Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC.
    Gut. 2022 Jun 15. pii: gutjnl-2021-326500. doi: 10.1136/gutjnl-2021-326500.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.